lyme disease

The CDC is now reporting that there are over 300,000 new cases of Lyme disease each year.

Additionally, as the disease remains difficult to identify and diagnose, the definitive number of people affected is currently unknown, making this the fastest growing infectious disease in the U.S.

The tick-borne bacterium or spirochete (Borrelia burgdorferi) is protected by the biofilm it creates to hide from the immune system, and can often lie dormant for years. Often antibiotic interventions alone fall short in providing much needed symptomatic relief.

Hyperbaric oxygen therapy (HBOT) has been shown to elevate tissue oxygenation, which can be lethal to this bacteria, increase white blood cell activity and enhance antimicrobial responses. Oxygen is essential in the killing of bacteria and by exponentially raising oxygen levels throughout the body, the efficiency of bactericidal action of white blood cells can be enhanced dramatically.

Clinical data and case reports have demonstrated the lasting benefits of HBOT for Lyme disease with the following:

AMELIORATE NEUROLOGICAL CONDITIONS WITH HBOT

Decreases Neuroinflammation
Enhances Short-Term Memory
Reduces Chronic Fatigue
Improves Concentration
Ameliorate Chronic Headaches
Lesses Depression
Moderates Insomnia

INCREASE MOBILITY WITH HBOT

Diminishes Inflammatory-related Arthritic Pain
Lessens Muscle Distance
Improves Walking Distance
Amplifies Energy Levels

ENHANCE ANTIBACTERIAL EFFECTS WITH HBOT

Induces Angiogenesis to Mobilize Blood Flow to Affected Tissue and Bone
Augments Antibiotic Interventions by Driving Spirochete Out of Biofilms
Enhances White Blood Cell and Immune System Activity
Improves Antibiotic Cell Wall Penetration
Increases Oxygen Free Radicals to Combat the Bb (Borrelia burgdorferi) Organism

Research

An exploratory trial, conducted at Texas A&M University, examined and evaluated the effects of HBOT for Lyme disease in 91 patients. All patients failed to respond to intravenous antibiotics and 67% of the patients remained on antibiotic treatment during the trial. Patients ranged from children to adults. At the completion of the trial, 75% of patients completed anywhere from 10-133 treatments (60 minutes, twice daily, five days a week). Approximately 85% showed a significant improvement by a decrease or elimination of symptoms. Most patients began to show major improvements after the reaction subsided and well beyond the conclusion of HBOT. Follow-up from 6 weeks to 6 years showed that benefits sustained in approximately 70% patients.

Clinical Research

The following research highlights the benefit of hyperbaric oxygen therapy for people who have Lyme disease.

Study